Hutch News: On The Path to a New-Generation Malaria Vaccine

By Mary Engel

Researchers may be one step closer to a truly effective malaria vaccine, a new study suggests. A genetically modified malaria parasite worked as designed in its first human clinical trial, causing neither malaria nor serious safety problems in the 10 people who volunteered to be infected. It also stimulated an immune response that holds out promise of a more protective vaccine than the single candidate now in pilot studies

SPH Close Up: Joel Kaufman, Interim Dean

Before he earned his MD, Joel Kaufman was a best-selling author — for a week, at least.

In 1982, he took a year off from his studies to work for the consumer advocacy Public Citizen Health Research Group in Washington, D.C. The result was a book, Over the Counter Pills That Don’t Work.

EurekAlert: Why Some People May Not Respond to the Malaria Vaccine

Creating protective immunity against the early liver stage of malaria infection is feasible, but has been difficult to achieve in regions with high rates of malaria infection. Many current malaria vaccines target the pre-erythrocytic stage of infection in the liver, however in endemic regions, increased blood stage exposure is associated with decrease vaccine efficacy, challenging current malaria vaccine efforts. 

The Lancet: Profile of Jared Baeten, Aiming to See Off HIV

By Tony Kirby

"The last person that I train, I want that training to be in something other than HIV", says Jared Baeten. Speaking to The Lancet Infectious Diseases from the HIV Research for Prevention Conference (HIVR4P) in Chicago, IL, where he brought a 12-strong team of his researchers, Baeten explains: “When that time comes, I want HIV to have been eliminated as public health threat, so we can focus on other diseases”. 

Pages